Thymosin Beta 4 is a recurring topic in our peptide coverage. This hub collects every article tagged Thymosin Beta 4, newest first, each evidence-graded and tied to real, verifiable sources.
Wound healing is one of the few peptide areas with genuine human controlled-trial data — but it is narrow, topical, and concentrated in chronic wounds. A clinical-editorial ranking of GHK-Cu, thymosin β4, LL-37 and BPC-157 by what the evidence actually supports in 2026.
An evidence-graded review of the peptides marketed for wrist sprains, tenosynovitis, TFCC tears and carpal tunnel syndrome. The honest 2026 verdict: no human RCT — indeed essentially no human data of any kind — exists; the case is entirely preclinical (rat tendon and sciatic-nerve models), and conventional care has the far stronger human evidence.
A clinical, evidence-first ranking of the peptides most promoted for healing surgical incisions and preventing scars — separating genuine human topical-wound data from animal-only signals and marketing.
An evidence-graded look at the peptides marketed for rotator-cuff tears and repair recovery — BPC-157, TB-500/Thymosin β4 and GHK-Cu — separating a single unpublished rat abstract and animal mechanism from anything resembling human proof.
A clinical, evidence-graded ranking of the peptides marketed for post-surgical recovery — thymosin alpha-1, thymosin β4/TB-500, GHK-Cu and BPC-157 — separating the one with human surgical RCT data from the rest, which are topical, negative, or preclinical only.
An evidence-graded review of the peptides marketed for whiplash and neck soft-tissue injury. The honest 2026 verdict: there is no human evidence — no RCT, cohort, or registered trial — for any peptide in the cervical spine; the strongest case tops out at rat ligament and tendon models.
A clinical, evidence-graded review of the peptides marketed for hamstring pulls, calf and quad strains, and muscle tears — where the animal data are genuinely muscle-specific, and why no completed human trial yet proves any of them heals a strain.
A clinical, evidence-graded review of the peptides marketed for sprains, MCL tears and ACL injury — where the rat data are genuinely ligament-specific, and why no human trial yet proves any of them heals a torn ligament.
An evidence-graded review of the peptides marketed for meniscus tears, ligament sprains, tendinopathy and cartilage wear. The honest 2026 verdict: no peptide has a placebo-controlled human knee trial — the strongest case is preclinical (rat surgery models) plus one uncontrolled human case series.
An evidence-graded review of the peptides marketed to 'injury-proof' tendons and ligaments. The honest 2026 verdict: prevention is the single most speculative claim in the peptide literature — no human prevention RCT, and no controlled animal prevention study, exists for any candidate.
An evidence-graded review of the peptides marketed for hip labral tears, femoroacetabular impingement, gluteal tendinopathy (GTPS) and hip bursitis. The honest 2026 verdict: no peptide has a human hip trial — the evidence tops out at animal models, while exercise and PRP hold the real human RCT data.
Thymosin beta-4 (RGN-259) is the rare peptide with real, large human RCTs for the ocular surface — yet every pivotal Phase 3 missed its co-primary endpoint. A clinical-editorial ranking of what the dry-eye evidence actually supports in 2026.
A clinical, evidence-graded review of the five peptides marketed for cardiovascular and heart health — elamipretide, angiotensin-(1-7), thymosin β4, TB-500 and BPC-157 — separating real human trials from preclinical and marketing claims.
LL-37, GHK-Cu, thymosin β4/TB-500 and BPC-157 all have real wound-healing biology — but not a single controlled human burn trial. A clinical-editorial ranking of what the evidence actually supports in 2026.
An evidence-graded review of the peptides marketed for ankle sprains, ATFL tears and Achilles injury. The honest 2026 verdict: no human RCT exists; the strongest case is preclinical (rat Achilles models), and PRP — not a peptide — has the better human ankle evidence.
A clinical monograph on Thymosin Beta-4 (Tβ4) — the actin-sequestering repair peptide with a real, decades-long human-trial record in ocular, dermal and cardiac repair. Grade B human evidence, no FDA-approved product, and an unsettled 2026 legal status.
A clinical monograph on Ac-SDKP (goralatide/seraspenide), the N-terminal tetrapeptide fragment of thymosin beta-4. Human chemoprotection data (Grade B), preclinical-only anti-fibrosis, and a WADA-prohibited 2026 status.
A clinical monograph on TB-500 — the synthetic thymosin β4 fragment (Ac-LKKTETQ) marketed for tendon, muscle and tissue repair. Strong preclinical biology, no human efficacy RCT of the fragment, and an unsettled 2026 legal status.
Thymosin Beta 4 is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Thymosin Beta 4, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.